Vitamin D and COVID-19 Severity
Separately from the prevention question (see our COVID page), research has examined whether vitamin D status modifies COVID-19 severity — hospitalisation, ICU admission, mortality. The picture is nuanced with observational deficiency associations but mixed trial evidence.
Observational severity data
Multiple observational studies (Radujkovic 2020, Meltzer 2021, and others) reported vitamin D-deficient patients had higher COVID hospitalisation, ICU admission, and mortality rates. Effect sizes varied — some cohorts found 2–3× higher mortality in the deficient after adjustment; others found no independent effect once age, obesity, and comorbidity were controlled.
Hospitalised-patient trials
- Castillo 2020 (Cordoba, Spain) — 76 hospitalised COVID patients randomised to calcifediol (25(OH)D3) or standard care. Calcifediol arm had dramatically lower ICU admission (2% vs 50%) and mortality (0% vs 7.6%). Small trial, single-centre, but striking.
- Murai 2021 (Brazil, COVIDIOL) — 240 hospitalised COVID patients; single 200,000 IU cholecalciferol bolus vs placebo. No difference in length of stay, mortality, or ICU admission.
- SHADE trial (India, 2021) — 40 asymptomatic COVID patients; 60,000 IU cholecalciferol daily × 7 days: improved viral clearance.
- CARED trial (Argentina, 2022) — 218 hospitalised patients; calcifediol vs standard: no significant benefit on primary endpoint.
The calcifediol vs cholecalciferol distinction
Positive severity signals came predominantly from calcifediol (already-25- hydroxylated vitamin D — bypasses hepatic activation and raises 25(OH)D within hours). Cholecalciferol bolus takes days to raise 25(OH)D. In acutely ill hospitalised patients, speed of repletion may matter. Calcifediol is not widely available OTC in the US; it is in some European countries.
Meta-analyses
2022 and 2023 meta-analyses of COVID vitamin D trials produced mixed conclusions — modest overall benefit signals with substantial heterogeneity. The Cochrane 2023 review concluded very-low certainty evidence for supplementation reducing severe outcomes.
Practical current guidance
- Correct vitamin D deficiency for the many established reasons — not specifically for COVID prevention or severity reduction.
- If admitted with COVID and known to be deficient: many hospitals now include repletion in their standard care.
- Vaccination remains the strongest-evidence COVID intervention.
- Do not use vitamin D as a substitute for vaccines, monoclonal antibodies, antivirals, or hospital care.